Biopharmaceutical company for rare genetic diseases
1 AI-extracted insight from 1 source — podcasts, YouTube channels, and X/Twitter accounts.
Based on 1 scored insight about Rhythm Pharmaceuticals, Inc..
The 1 sources with the most insights about Rhythm Pharmaceuticals, Inc. on Kazuha.
AI-generated insights from podcasts, YouTube videos, and X posts — ordered by most recent.
Analyst holds a small position but doubts the success of their Angelman syndrome drug.
Analyst holds a small position but doubts the success of their Angelman syndrome drug.
Other assets that creators frequently mention in the same content as Rhythm Pharmaceuticals, Inc..
The most active sources covering Rhythm Pharmaceuticals, Inc. (RYTM) on Kazuha are @realmartinshkreli. Kazuha aggregates AI-extracted insights from podcasts, YouTube channels, and X/Twitter accounts.
Kazuha has indexed 1 AI-extracted insight about Rhythm Pharmaceuticals, Inc. (RYTM) from 1 different source. New insights are added whenever a covered creator publishes a new podcast episode, video, or post.
Creators covering Rhythm Pharmaceuticals, Inc. (RYTM) most frequently also discuss HUBS, AMD, MARA, TXG, SION. See the "Discussed alongside" section above for full asset pages.